Savara's aPAP Patient Journey Map Accepted for CHEST 2024 Poster Presentation

Savara Inc., a clinical-stage biopharmaceutical company listed on Nasdaq under the symbol SVRA, is dedicated to developing treatments for rare respiratory diseases. The company recently announced that its abstract has been accepted for a poster presentation at the CHEST 2024 Annual Meeting in Boston, scheduled from October 6-9. Savara will also sponsor an Industry Symposium during the event. Here are the details:

**Accepted Abstract**:
- **Title**: "A Patient Journey Map for People Living with Autoimmune Pulmonary Alveolar Proteinosis (aPAP)"
- **Poster Session**: Diffuse Lung Disease Abstracts Posters (D)
- **Date and Time**: October 8, 2024, from 1:45 to 2:30 pm EDT

**Company-Sponsored Symposium**:
- **Title**: "Pulmonary Alveolar Proteinosis: Pathophysiology, Diagnosis, and Management"
- **Location**: CHEST Learning Theater
- **Date and Time**: October 8, 2024, from 2:00 to 2:45 pm EDT
- **Speaker**: Dr. Ali Ataya, Associate Professor of Medicine at the University of Florida, Division of Pulmonary and Critical Care Medicine

**About Autoimmune PAP (aPAP)**:
Autoimmune Pulmonary Alveolar Proteinosis (aPAP) is a rare lung disorder marked by the abnormal accumulation of surfactant in the alveoli, the tiny air sacs in the lungs. Surfactant is a mixture of proteins and lipids that keeps the alveoli from collapsing. In healthy lungs, alveolar macrophages, stimulated by granulocyte-macrophage colony-stimulating factor (GM-CSF), clear out excess surfactant. However, in autoimmune PAP, antibodies against GM-CSF neutralize this factor, preventing the macrophages from functioning correctly. This leads to a buildup of surfactant, impairing gas exchange and causing symptoms like shortness of breath, cough, and fatigue. Patients may also experience fever, chest pain, or hemoptysis (coughing up blood), particularly if they develop secondary lung infections. Over time, the disease can cause severe complications, including lung fibrosis and the potential need for a lung transplant.

**About Savara**:
Savara Inc. is focused on developing treatments for rare respiratory diseases. Their flagship program involves molgramostim inhalation solution, an inhaled form of GM-CSF currently in Phase 3 clinical development for autoimmune PAP. Molgramostim is administered through an investigational eFlow® Nebulizer System developed by PARI Pharma GmbH. The company's management team has extensive expertise in rare respiratory diseases and pulmonary medicine, enabling them to identify unmet medical needs and advance their product candidates toward approval and commercialization.